Imaging techniques in the evaluation and management of hypertrophic cardiomyopathy

Current Heart Failure Reports

Volumn 6, Issue 3, 2009, Pages 135-141

  Kelley Hedgepeth, Alyson ^a   Maron, Martin S ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; AMMONIA N 13; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GADOLINIUM; RUBIDIUM 82; TECHNETIUM 99M; WATER O 15;

CINEANGIOCARDIOGRAPHY; CONTRAST ENHANCEMENT; DEFIBRILLATOR; DIASTOLIC DYSFUNCTION; DOPPLER ECHOCARDIOGRAPHY; ECHOCARDIOGRAPHY; EXERCISE ELECTROCARDIOGRAPHY; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FILLING PRESSURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART MUSCLE FIBROSIS; HEART MUSCLE PERFUSION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MITRAL VALVE REGURGITATION; MUSCLE RESECTION; NUCLEAR MAGNETIC RESONANCE; POSITRON EMISSION TOMOGRAPHY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTOLIC DYSFUNCTION; TRANSTHORACIC ECHOCARDIOGRAPHY; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

CARDIOMYOPATHY, HYPERTROPHIC; DIAGNOSTIC IMAGING; ECHOCARDIOGRAPHY, DOPPLER; ECHOCARDIOGRAPHY, TRANSESOPHAGEAL; FIBROSIS; HEART; HEART SEPTUM; HUMANS; MAGNETIC RESONANCE IMAGING; MYOCARDIUM; RETROSPECTIVE STUDIES; VENTRICULAR DYSFUNCTION; VENTRICULAR OUTFLOW OBSTRUCTION;

EID: 69549138150     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-009-0020-x     Document Type: Review

References (50)

1. Marian AJ, Roberts R: Recent advances in the molecular genetics of hypertrophic cardiomyopathy. Circulation 1995, 92:1336-1347.
2. Maron BJ, Gottdiener JS, Epstein SE: Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy. A wide angle, two dimensional echocardiographic study of 125 patients. Am J Cardiol 1981, 48:418-428.
3. Maron BJ, McKenna WJ, Danielson GK, et al.: American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 2003, 42:1687-1713.
4. Wigle ED, Sasson Z, Henderson MA, et al.: Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review. Prog Cardiovasc Dis 1985, 28:1-83.
5. Shapiro LM, McKenna WJ: Distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: A twodimensional echocardiographic study. J Am Coll Cardiol 1983, 2:437-444.
6. Adelman AG, McLoughlin MJ, Marquis Y, et al.: Left ventricular cineangiographic observations in muscular subaortic stenosis. Am J Cardiol 1969, 24:689-697.
7. Braunwald E, Lambrew CT, Rockoff SD, et al.: Idiopathic hypertrophic subaortic stenosis. I. A description of the disease based upon an analysis of 64 patients. Circulation 1964, 30(Suppl 4): 3-119.
8. Maron BJ: Hypertrophic Aardiomyopathy: a systematic review. JAMA 2002, 287:1308-1320.
9. Shah PM, Gramiak R, Kramer DH: Ultrasound localization of left ventricular outflow obstruction in hypertrophic obstructive cardiomyopathy. Circulation 1969, 40:3-11.
10. Klues HG, Roberts WC, Maron BJ: Morphological determinants of echocardiographic patterns of mitral valve systolic anterior motion in obstructive hypertrophic cardiomyopathy. Circulation 1993, 87:1570-1579.
11. Klues HG, Schiffers A, Maron BJ: Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: Morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol 1995, 26:1699-1708.
12. Pollick C, Rakowski H, Tigle ED: Muscular subaortic stenosis: the quantitative relationship between systolic anterior motion and the pressure gradient. Circulation 1984, 69:43-49.
13. Wigle ED, Rakowski H, Kimball BP, Williams WG: Hypertrophic cardiomyopathy. Clinical spectrum and treatment. Circulation 1995, 92:1680-1692.
14. Moon JC, Fisher NG, McKenna WJ, Pennell DJ: Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. Heart 2004, 90:645-649.
15. Rickers C, Wilke NM, Jerosch-Herold M, et al.: Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation 2005, 112:855-861.
16. Spirito P, Bellone P, Harris KM, et al.: Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000, 342:1778-1785.
17. Sorajja P, Nishimura RA, Ommen SR, et al.: Use of echocardiography in patients with hypertrophic cardiomyopathy: Clinical implications of massive hypertrophy. J Am Soc Echocardiogr 2006, 19:788-795.
18. Maron BJ, Seidman JG, Seidman CE: Proposal for contemporary screening strategies in families with hypertrophic cardiomyopathy. J Am Coll Cardiol 2004, 44:2125-2132.
19. Maron MS, Olivotto I, Zenovich AG, et al.: Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 2006, 114:2232-2239.
20. Spirito P, Maron BJ: Patterns of systolic anterior motion of the mitral valve in hypertrophic cardiomyopathy: Assessment by two-dimensional echocardiography. Am J Cardiol 1984, 54:1039-1046.
21. Schwammenthal E, Nakatani S, He S, et al.: Mechanism of mitral regurgitation in hypertrophic cardiomyopathy: Mismatch of posterior to anterior leaflet length and mobility. Circulation 1998, 98:856-865.
22. Sherrid MV, Chaudhry FA, Swistel DG: Obstructive hypertrophic cardiomyopathy: Echocardiography, pathophysiology, and the continuing evolution of surgery for obstruction. Ann Thoracic Surg 2003, 75:620-632.
23. Maron BJ, Gottdiener JS, Arce J, et al.: Dynamic subaortic obstruction in hypertrophic cardiomyopathy: Analysis by pulsed Doppler echocardiography. J Am Coll Cardiol 1985, 6:1-18.
24. Maron MS, Olivotto I, Betocchi S, et al.: Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003, 348:295-303.
25. Ommen SR, Maron BJ, Olivotto I, et al.: Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005, 46:470-476.
26. Maron BJ, Nishimura RA, Danielson GK: Pitfalls in clinical recognition and a novel operative approach for hypertrophic cardiomyopathy with severe outflow obstruction due to anomalous papillary muscle. Circulation 1998, 98:2505-2508.
27. Yu EH, Omran AS, Wigle ED, et al.: Mitral regurgitation in hypertrophic obstructive cardiomyopathy: Relationship to obstruction and relief with myectomy. J Am Coll Cardiol 2000, 36:2219-2225.
28. Grigg LE, Wigle ED, Williams WG, et al.: Transesophageal Doppler echocardiography in obstructive hypertrophic cardiomyopathy: clarification of pathophysiology and importance in intraoperative decision making. J Am Coll Cardiol 1992, 20:42-52.
29. Kimmelstiel CD, Maron BJ: Role of percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. Circulation 2004, 109:452-456.
30. Faber L, Seggewiss H, Gleichmann U: Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Results with respect to intraprocedural myocardial contrast echocardiography. Circulation 1998, 98:2415-2421.
31. Nagueh SF, Lakkis NM, He ZX, et al.: Role of myocardial contrast echocardiography during nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1998, 32:225-229.
32. Seggewiss H, Gleichmann U, Faber L, et al.: Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients. J Am Coll Cardiol 1998, 31:252-258.
33. Qin JX, Shiota T, Lever HM, et al.: Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. J Am Coll Cardiol 2001, 38:1994-2000.
34. Briguori C, Betocchi S, Losi MA, et al.: Noninvasive evaluation of left ventricular diastolic function in hypertrophic cardiomyopathy. Am J Cardiol 1998, 81:180-187.
35. Nagueh SF, Lakkis NM, Middleton KJ, et al.: Doppler estimation of left ventricular filling pressures in patients with hypertrophic cardiomyopathy. Circulation 1999, 99:254-261.
36. Geske JB, Sorajja P, Nishimura RA, Ommen SR: Evaluation of left ventricular filling pressures by Doppler echocardiography in patients with hypertrophic cardiomyopathy: Correlation with direct left atrial pressure measurement at cardiac catheterization. Circulation 2007, 116:2702-2708.
37. Harris KM, Spirito P, Maron MS, et al.: Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation 2006, 114:216-225.
38. O'Gara PT, Bonow RO, Maron BJ, et al.: Myocardial perfusion abnormalities in patients with hypertrophic cardiomyopathy: Assessment with thallium-201 emission computed tomography. Circulation 1987, 76:1214-1223.
39. Sorajja P, Chareonthaitawee P, Ommen SR, et al.: Prognostic utility of single-photon emission computed tomography in adult patients with hypertrophic cardiomyopathy. Am Heart Journal 2006, 151:426-435.
40. Cannon RO, Dilsizian V, O'Gara PT, et al.: Myocardial metabolic, hemodynamic, and electrocardiographic significance of reversible thallium-201 abnormalities in hypertrophic cardiomyopathy. Circulation 1991, 83:1660-1667.
41. Camici P, Chiriatti G, Lorenzoni R, et al.: Coronary vasodilation is impaired in both hypertrophied and nonhypertrophied myocardium of patients with hypertrophic cardiomyopathy: A study with nitrogen-13 ammonia and positron emission tomography. J Am Coll Cardiol 1991, 17:879-886.
42. Basso C, Thiene G, Corrado D, et al.: Hypertrophic cardiomyopathy and sudden death in the young: Pathologic evidence of myocardial ischemia. Human Pathol 2000, 31:988-998.
43. Cecchi F, Olivotto I, Gistri R, et al.: Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 2003, 349:1027-1035.
44. Olivotto I, Cecchi F, Gistri R, et al.: Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy. J Am Coll Cardiol 2006, 47:1043-1048.
45. Lima JA, Desai MY: Cardiovascular magCetic resonance imaging: current and emerging applications. J Am Coll Cardiol 2004, 44:1164-1171.
46. Moon JC, Reed E, Sheppard MN, et al.: The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 2004, 43:2260-2264.
47. Maron MS, Buros J, Gibson CM, et al.: Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Circulation 2008, 1:184-191.
48. Olivotto I, Maron MS, Autore C, et al.: Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 2008, 52:559-566.
49. Choudhury L, Mahrholdt H, Wagner A, et al.: Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002, 40:2156-2164.
50. Adabag AS, Maron BJ, Appelbaum E, et al.: Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol 2008, 51:1369-1374.